Rare Daily Staff
AI intelligence platform provider Pangaea Data has entered into a collaboration agreement with Alexion, AstraZeneca Rare Disease to develop, clinically validate, and obtain regulatory approval for an Artificial Intelligence Clinical Decision Support System designed to improve detection of adults with the rare condition hypophosphatasia.
As part of this collaboration, Alexion will provide the funding for the development of the system.
Hypophosphatasia (HPP) is an inherited disorder resulting from alkaline phosphatase (ALP) deficiency, or low ALP. It is associated with reduced bone mineralization, impaired energy metabolism, and compromised neurotransmitter function. The manifestations of HPP can be wide-ranging, and the disease often remains undiagnosed or misdiagnosed due to its diverse and non-specific symptoms.
By leveraging AI and clinical guidelines, the AI-CDSS developed by Pangaea Data in collaboration with Alexion will seek to improve the detection of HPP in adults based on information from electronic health records. With improved detection, adults living with HPP could receive a more timely diagnosis and clinical intervention, ultimately achieving better health outcomes.
“Adults living with a rare disease such as HPP often wait years to receive an accurate diagnosis because of the complex nature, varied symptoms, and limited awareness of the condition, a journey that is inherently inequitable,” said Seng Cheng, senior vice president, head of research and product development for Alexion. “We are committed to supporting potential solutions to help enable accurate and timely diagnoses, which can make a critical impact in the ability to treat patients, and we look forward to advancing this collaboration with Pangaea Data.”
Photo: Seng Cheng, senior vice president, head of research and product development for Alexion
Stay Connected
Sign up for updates straight to your inbox.